CERO THERAPEUTICS HOLDINGS, INC.

CERO Therapeutics Holdings, Inc. (Nasdaq: CERO) is a clinical-stage biopharmaceutical company focused on developing chimeric engulfment receptor T-cell (CER-T) therapies for hematologic malignancies and solid tumors. The company entered public markets through a business combination with Phoenix Biotech Acquisition Corp (PBAX), a blank-check company sponsored by Phoenix Biotech Sponsor LLC that completed its IPO in 2021. The de-SPAC transaction closed in early 2024, transitioning CERO into a post-combination oncology-focused public entity. The December 2025 DEFA14A filing represents additional definitive proxy soliciting material submitted to the SEC. For comprehensive SPAC transaction records, sponsor profiles, and filing timelines on CERO and the broader de-SPAC universe, sign up for full data access at SpacDesk.